AstraZeneca Pharma India has received Import and Market permission in Form 45 (Marketing Authorization) from the Drugs Controller General of India for FDC of Dapagliflozin 10mg + Saxagliptin 5mg film-coated tablets.
The receipt of this Import and Market permission paves way for the launch of FDC of Dapagliflozin 10mg + Saxagliptin 5mg film-coated tablets (QTERN®) in India, subject to the receipt of other related statutory approvals and licenses.
The scrip opened at Rs2,193 and has touched a high and low of Rs2,216.85 and Rs2,185.10 respectively. So far 6,045 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs5,379.25cr.
Quick Trial – 9407533858
or mail us here - support@ethicalresearch.co.in
or visit - http://ethicalresearch.co.in/home/freetrial
The receipt of this Import and Market permission paves way for the launch of FDC of Dapagliflozin 10mg + Saxagliptin 5mg film-coated tablets (QTERN®) in India, subject to the receipt of other related statutory approvals and licenses.
The scrip opened at Rs2,193 and has touched a high and low of Rs2,216.85 and Rs2,185.10 respectively. So far 6,045 (NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs5,379.25cr.
Quick Trial – 9407533858
or mail us here - support@ethicalresearch.co.in
or visit - http://ethicalresearch.co.in/home/freetrial
Comments
Post a Comment